Business Wire

mPrest and Vector, New Zealand's Largest Power Utility, Sign Contract to Bring “Internet of Energy” to Over a Million Customers


mPrest, a global provider of mission-critical ‘Internet of Energy’ software, today announced that its Distributed Energy Resource Management product – mDERMS, will be deployed in Vector's intelligent grid. Vector is New Zealand’s leading multi-network infrastructure company, which distributes energy and communication services to over 1.2 million homes and businesses. mDERMS will enable Vector to improve operational efficiencies and in time, offer new services to its customers such as: home energy optimization, choice of clean energy, grid contribution and energy trading.

“This project represents a new level of software control for the power utility sector,” said mPrest Chief Commercial Officer Ron Halpern. “mPrest will bring all of Vector’s distributed energy resources (DERs) together, yielding a single situational overview while providing maximal utilization of these distributed resources. This new level of control will allow Vector to make progress towards its goal of expanding access to participative energy markets for its customers, save CAPEX and OPEX in developing its digital power grid, and improve services and create new offerings to its customers.”

The mDERMS platform will unify Vector’s varied energy resources including solar photovoltaic systems, next generation storage and demand response onto a single distributed command and control system. mPrest will also integrate Vector’s internal operations platforms, including GIS, distribution automation and asset health management onto a single information technology (IT) and operational technology (OT) integrated system for control and maximum efficiency, cost and risk reduction for Vector, while increasing choice and reducing energy bills for its customers.

Vector Chief Executive Simon Mackenzie said the company is focused on creating a new energy future for its customers and the mDERMS platform is another step toward that.

“It is the most comprehensive monitoring, analytical and control system available anywhere in the world. We have worked with mPrest to trial it and we are now moving to full implementation. In addition, we will jointly develop the system not only for our customers but others,” Mr Mackenzie said.

“You can think of it as a system of systems. The software sits over customer, market, and network systems managing performance in real time. Through self-learning, it is able to assess and predict multiple factors including loads, market dynamics, storage, customer demand and capacity. This greatly enhances the resilience, security and efficiency of customer solutions and our network.”

With the evolution of the smart home creating new opportunities for intelligent energy use, customers are expecting more choice from their providers and the capability to have more control over the way they store and use energy. With the help of the new mDERMS platform, Vector is democratizing the smart grid by making energy generation and even participation in energy markets accessible to all its customers.

“mPrest’s revolutionary software increases a utility’s efficiency, productivity and response times. Our products create significant advantages and differentiators for our customers and we look forward to building this bright new energy future together with Vector,” said mPrest Chief Executive Officer Natan Barak.

About mPrest

mPrest is a global provider of mission-critical monitoring, control and big data analytics software. Leveraging vast field-proven Industrial IoT experience, mPrest's integrative system of systems is deployed in diverse sectors including utilities, critical infrastructure protection and defense. mPrest excels at connecting the dots across multiple disciplines and departments – delivering unified situational awareness, sophisticated analytics, and end to end IT/OT integration and process management. In the defense sector, mPrest is the software provider for the legendary Iron Dome anti-missile system. mPrest’s leadership in the “Internet of Energy” recently received further confirmation with the announced partnership with the New York Power Authority (NYPA) where mPrest is being used to manage transformer asset health throughout the grid. For more information on mPrest, visit

About Vector Limited

Vector is New Zealand’s leading multi-network infrastructure company which delivers energy and communication services to more than one million homes and businesses. The company owns and manages a unique portfolio which consists of electricity and gas distribution, electricity and gas metering and data management services, natural gas and LPG and fibre optic networks. Vector is listed on the New Zealand Stock Exchange with ticker symbol VCT. For further information, visit

Contact information

Josh Garrett, 646-957-5371

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on